NVO - Novo Nordisk A/S

NYSE - Nasdaq Real Time Price. Currency in USD
60.12
-0.97 (-1.58%)
As of 12:06PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close61.08
Open60.13
Bid60.15 x 1000
Ask60.16 x 1300
Day's Range59.99 - 60.27
52 Week Range46.10 - 62.69
Volume432,960
Avg. Volume1,429,640
Market Cap143.34B
Beta (5Y Monthly)0.59
PE Ratio (TTM)24.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.25 (2.05%)
Ex-Dividend DateMar 21, 2019
1y Target EstN/A
All
News
Press Releases
  • Novo Nordisk's new insulin affordability offerings now available in the US
    PR Newswire

    Novo Nordisk's new insulin affordability offerings now available in the US

    Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offering to help people with diabetes who need alternative solutions. These options, along with information on the existing patient assistance program, copay cards, and where to find $25/vial human insulin, are now available online at NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).

  • New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
    PR Newswire

    New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

    PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make people more – or less – prone to developing type 2 diabetes, paving the way for more targeted interventions to prevent disease. As part of Cities Changing Diabetes, a global program sponsored by Novo Nordisk involving 25 cities around the world, these groups will be working together to develop new ways to try to change the trajectory of diabetes in Philadelphia.

  • New international study: The hidden burden of diabetes on family members revealed
    CNW Group

    New international study: The hidden burden of diabetes on family members revealed

    MISSISSAUGA, ON , Sept. 10, 2019 /CNW/ - People living with diabetes are not the only ones impacted by the condition. Low blood sugar or "lows" as they are often referred to by people living with diabetes, are a well-known side-effect of diabetes treatment, especially when using insulin, and they can be very unpleasant and dangerous if not managed properly.

  • Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral
    PR Newswire

    Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral

    BOSTON, Aug. 14, 2019 /PRNewswire/ -- Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where companies develop truly transformational science. Novo Nordisk, a global healthcare company committed to discovering, creating and co-creating innovation to solve healthcare challenges for people living with diabetes and other serious chronic diseases, issues an open call for promising start-up companies to submit non-confidential proposals for a Novo Nordisk-sponsored LabCentral "Golden Ticket." The winner will have the chance to receive access for one scientist and one bench at LabCentral's state-of-the-art shared lab space in Boston for research for one year.

  • Renewable electricity to completely power Novo Nordisk US operations in early 2020
    PR Newswire

    Renewable electricity to completely power Novo Nordisk US operations in early 2020

    PLAINSBORO, N.J., April 30, 2019 /PRNewswire/ -- Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero carbon emissions from operations and transportation. The announcement follows a $70 million investment in a 105-megawatt dc solar energy installation to be built in Pender County, North Carolina. When completed, ground-mounted solar arrays will harvest sunlight and provide renewable electricity to all existing Novo Nordisk US offices, laboratories and manufacturing facilities as well as to support the new manufacturing facility under construction in Clayton, N.C. Developed and constructed by Cypress Creek Renewables, the solar panel installation will be one of North Carolina's largest solar sites.

  • PR Newswire

    Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents

    PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.

  • GlobeNewswire

    Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.